Comment: I would like to suggest the coverage for Macugen be extended to the treatment of diabetic macular edema. Macugen is a selective anti-VEGF drug which has been approved for the use in exudative ARMD. The injection of Macugen in the treatment of diabetic macular edema has been shown to be effective in improving the vision of patients with diabetic macular edema in the recently published a...

Diabetic macular edema (DME) is arguably one of the most important challenges in ophthalmology. Macular edema refractory to laser photocoagulation remains the most prevalent cause of untreatable vision loss in diabetes and is responsible for visual disability in millions of people worldwide. The lack of an effective therapeutic solution accounts for the range of interventions proposed. These in...

UNLABELLED Diabetic macular edema (DME), one the most prevalent causes of visual loss in industrialized countries, may be diagnosed at any stage of diabetic retinopathy. The diagnosis, treatment, and follow up of DME have become straightforward with recent developments in fundus imaging, such as optical coherence tomography. Laser photocoagulation, intravitreal injections, and pars plana vitrec...

Diabetic macular edema (DME) remains the most common cause of vision loss among diabetic patients. New understanding of the underlying pathophysiology has interest in the potential benefits of the specific pharmacologic therapy, such as treatment with intraocular steroids, anti-vascular endothelial growth factor (VEGF), and protein kinase C-beta (PKCβ) inhibition. At the last time, laser photoc...

BACKGROUND The major cause of visual impairment in diabetic patients is macular edema. The failure of laser photocoagulation in a large subgroup of patients with clinically significant diabetic macular edema has prompted interest in other treatment methods. OBJECTIVES To evaluate the long-term efficacy and safety of an intravitreal injection of triamcinolone acetonide for clinically significa...

BACKGROUND The purpose of this retrospective chart review was to evaluate factors associated with improvement of visual acuity after a single sub-Tenon injection of triamcinolone acetonide in patients with diabetic macular edema. METHODS We reviewed the medical records for 63 consecutive eyes with diabetic macular edema treated by sub-Tenon injection of triamcinolone acetonide and assessed at...

Background: 26 million people were estimated to be affected by diabetes in 2010 across the globe. Diabetic macular edema (DME) is the most important cause of visual impairment due to diabetic retinopathy. Optical Coherence Tomography (OCT) is a non-invasive modality which produces cross-sectional or three-dimensional, high-resolution images of the retinal layers and quantitative assessment of r...

OBJECTIVE To explore the multifocal electroretinogram in patients with nonproliferative diabetic retinopathy with clinically-significant macular edema. METHODS Forty-one eyes with clinically significant macular edema were tested. The latencies and amplitudes of average responses of 5 eccentric rings from 0 to 26 degrees relative to the fixation point were compared with normal values obtained ...

PURPOSE Triamcinolone acetonide (TA) is an alternative option for diabetic macular edema thanks to its cost-benefit ratio and unique delivery route. We performed this study to compare vitrectomized with nonvitrectomized eyes treated with subtenon TA injection for diabetic macular edema. MATERIALS AND METHODS We retrospectively reviewed the medical records of patients who had undergone subteno...

PURPOSE To compare the visual acuity and macular thickness in patients with diabetic retinopathy presenting and not presenting macular edema before treatment and submitted to argon laser retinal panphotocoagulation. METHODS Patients were included and classified into two groups before the treatment. All patients were submitted to ophthalmological examination and optical coherence tomography, f...